Efficacy and Safety of Changfu Peritoneal Dialysis Solution: a Multi-Center Prospective Randomized Controlled Trial.
Zhou Jian-hui,Ni Zhao-hui,Mei Chang-lin,Yu Xue-qing,Liu Fu-you,Miao Li-ning,Liu Zhi-hong,Yuan Wei-jie,Zhang Ai-ping,Lin Hong-li,Chen Meng-hua,Chen Jiang-hua,Zhang Jin-yuan,He Ya-ni,Chen Jian,Zhao Jiu-yang,Ding Xiao-qiang,Li Ying,Li Rong-shan,Xie Ru-juan,Liu Wen-hu,Xing Chang-ying,Wang Rong,Deng Yue-yi,Cao Xue-ying,Cai Guang-yan,Mou Shan,Mao Zhi-guo,Yang Xiao,Liu Hong,Sun Jing,Yu,Liu Jun,Shi Shu-mei,Li Long-kai,Tian Na,Zhang Xiao-hui,Zhou Wei,Yang Jie,Zhang Yong,Sun Jing-di,Ji Jun,Zhang Tao,Yan,Liu Xiao-gang,Wang Gang,Zhang Li,Zhang Hong,Luo Jian-hua,Chen Xiang-mei
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20131722
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Background A multi-center large scale study is needed to confirm the efficacy and safety of domestic peritoneal dialysis (PD) solutions. Some researchers believe that 6 L/d is enough for adequate dialysis, but there is no multi-center prospective study on Chinese population to confirm this. In this study, we evaluated the efficacy and safety of domestic PD solution (Changfu) and its difference between 6 L and 8 L dosage. Methods Adult PD patients who had taken PD therapy for at least one month were selected and divided into four groups according to two dialysis solution brands and two dialysis dosages, i.e., 6 L dose with Changfu dialysis solution, 6 L dose with Baxter dialysis solution, 8 L dose with Changfu dialysis solution, and 8 L dose with Baxter dialysis solution. After 48 weeks, the changes of primary and secondary efficacy indices were compared between different types and different dosages. We also analyzed the changes of safety indices. Results Changes of Kt/V from baseline to 48 weeks between Changfu and Baxter showed no statistical differences; so did those of creatinine clearance rate (Ccr). Normalized protein catabolic rate (nPCR) from baseline to 48 weeks between Changfu and Baxter showed no statistical differences; so did those of net ultrafiltration volume (nUF) and estimated glomerular filtration rate (eGFR). Changes of nPCR from baseline to 48 weeks between 6 L and 8 L showed no statistical differences; so did those of nUF and eGFR. The decline of Kt/V from baseline to 48 weeks in 6 L group was more than that in 8 L group. Change of Ccr was similar. During the 48-week period, the mean Kt/V was above 1.7/w, and mean Ccr was above 50 L·1.73 m-2w-1. More adverse events were found in Changfu group before Changfu Corporation commenced technology optimization, and the statistical differences disappeared after that. Conclusions The domestic PD solution (Changfu) was proven to be as effective as Baxter dialysis solution. During 48-week period, a dosage of 6 L/d was enough for these patients to reach adequate PD. Clinical study promotes technological optimization, further helps to improve the safety indices of the medical products.